Mnemosyne Pharmaceuticals Garners $5,400,000 Series A Financing
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=218e4cfe-e65c-4289-aff4-d76db40f316f&Preview=1 - Date
2/17/2012 - Company Name
Mnemosyne Pharmaceuticals - Mailing Address
3 Davol Square Providence, RI 02903 - Company Description
The company is a Providence-based drug discovery venture aiming to develop small molecule therapeutics to treat schizophrenia and other cognitive and neuropsychiatric disorders. - Website
http://www.mnemosynepharma.com - Transaction Type
Venture Equity - Transaction Amount
$5,400,000 - Transaction Round
Series A - Proceeds Purposes
The company said that it will use the new funds in support of its drug discovery programs, including the identification of lead product candidates for treatment of schizophrenia and other neuropsychiatric disorders. - M&A Terms
- Venture Investor
Access BridgeGap Ventures - Venture Investor
Slater Technology Fund
